足叶乙甙联合顺铂治疗广泛期小细胞肺癌的临床效果观察  

Etoposide Combined Cisplatin Treatment Widely Stage Small Cell Lung Cancer Clinical Effect Observation

作　　者：田军[1] 

机构地区：[1]山东省安丘市人民医院,山东安丘262100

出　　处：《中国医药指南》2014年第20期28-28,30,共2页Guide of China Medicine

摘　　要：目的观察足叶乙甙联合顺铂治疗广泛期小细胞肺癌的疗效及安全性。方法选择56例未经抗肿瘤治疗的广泛期SCLC患者采用足叶乙甙联合顺铂治疗,2个周期后评价疗效及不良反应。结果 56例患者中CR21例,PR18例,SD11例,PD6例,RR为69.64%,DCR为89.29%;所有患者中出现白细胞减少4例,恶心、呕吐6例,肾毒性3例及神经毒性2例,经治疗后未见有影响治疗的情况发生,不良反应发生率为26.79%。结论足叶乙甙联合顺铂用于一线治疗广泛期SCLC有较好的疗效,安全性较好,可以临床推广。ObjectiveTo observe etoposide combined cisplatin treatment widely curative effect and safety of stage small cell lung cancer.Methods56 cases of extensive SCLC patients without anti-tumor treatment with etoposide combined cisplatin treatment, evaluation of curative effect and adverse reaction after 2 cycles.Results56 cases CR21, PR18, SD11 example, PD6 example, RR was 69.64%, the DCR is 89.29%; in all patients with leukopenia 4 cases, 6 cases of nausea and vomiting, renal toxicity of 3 cases and neurotoxicity in 2 cases, the treatment effect has been observed before and after the treatment, the incidence of adverse reactions was 26.79%.ConclusionEtoposide combined cisplatin for ifrst-line treatment phase extensive SCLC has good curative effect, security is good, can be clinical promotion.

关 键 词：足叶乙甙 顺铂 小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]